Shaik, R., Bilal, A. T., (2012). ‘‘Nanomedicine current trends in diabetes management’’, J. Nanomed. Nanotech., 3: 1-7.
Gangadhara, A. R., Subashini., (2014). “Transdermal Nanocarriers: New Challenges and Prospectives in the Treatment of Diabetes mellitus”, J. of Chem. and App. Biochem.,1: 1-11.
Silvio, E., Inzucchi., (2015). “Management of hyperglycemia in Type 2 diabetes. A patient centered approach”, Diabetes Care., 38: 140-149.
Sajeev, K. B., Saraswathi, R., (2013). “Development and characterization of lecithin stabilized glibenclamide nanocrystals for enhanced solubility and drug delivery”, Drug Delivery., 21: 173-184.
Williams, R. O., (2012). “Preface in formulating poorly water-soluble drugs”, Springer, USA.
Thomas, T., Jennifer, B., (2012). “New formulation approaches to improve solubility and drug release from fixed dose combinations: case examples, Pioglitazone / glimepiride and ezetimibe / simvastatin”, Eur. J. Pharm. Biopharm., 84: 208-18.
Gülsun, T., Gürsoy, R. N., (2009). “Öner. Nanocrystal technology for oral delivery of poorly water soluble drugs”, J. Pharm. Sci., 34: 55-65.
Chen, H., Khemtong, C., Yang, X., (2011). “Nanonization strategies for poorly water soluble drugs”, Drug Discov. Today., 16: 354-60.
Faris, N. B., Müller, R. H., (2002). “Nanocrystals for poorly soluble drugs for oral administration”, New Drugs., 2: 20-21.
Melike, Ü., Gülgün, Y., (2007). “Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives”, Int. J. Nanomed., 2: 289-300.
Mishra, B., Bhavesh, P.,(2010). “Colloidal nanocarriers- a review on formulation technology, types and applications towards targeted drug delivery”, Nanomed, Nanotechnol. Biomed., 6: 9-24.
Fillipos, K., Santipharp, P., (2007). “Nanosizing oral formulation development and biopharmaceutical evaluation”. Adv. Drug Deliver. Rev., 59: 631-644.
Faris, N. B., Rainer, R. H., (2002). “Nanocrystals technology drug delivery and clinical applications”. Int. J. of Nanomed., 3: 295-309.
Mohanraj, V. J., Chen, Y.,(2006). “Nanoparticles - A Review”, Trop. J. Pharm. Res., 5: 561-573.
Sandrine, D., Lucie, S., (2012). “Physico-chemical parameters that govern nanoparticles fate also dictate rules for their molecular evolution”, Adv. Drug Deliver. Rev., 64: 179-189.
Zheng, N., Gao, X., Song, Q., (2012). “Lipid - based liquid crystalline nanoparticles as oral drug delivery vehicles for poorly water - soluble drugs, cellular interaction and in vivo absorption”, Int. J. Nano. Med., 7: 3703-3718.
Huabing, C., Chalermachai, K., (2011). “Nanonization strategies for poorly water soluble drugs”, Drug Discov. Today., 16: 354-360.
Libo, W., Jian, Z., (2011). “Physical stability of nanoparticles”, Adv. Drug Deliver. Rev., 63: 456-469.
Frick, A., Moller, H., Wirbitzki, E., (1998). “Biopharmaceutical characterization of oral immediate release drug products. Invitro/invivo comparison of phenoxymethyl pencillin, glimepirdie and levofloxacin”. Eur. J. of Pharm. Biopharm., 46: 305-311.
Hai, W., Chad, D., (2008). “Physiochemical characterization of five glyburide powders. A BCS based approach to predict oral absorption”. Eur. J. of Pharm. Biopharm., 46: 305-311.
Patrick, J. C., Luigi, G. M., (2004). “Formulation design: new drugs from old. Drug discov. today, therap. and strategies., 1: 537-542.
O'Donnell, K. P., (2012).“Optimizing the formulation of poorly water - soluble drugs”., Springer, USA.
Otilia, M. K., (2005). “Role of nanotechnology in targeted drug delivery and imaging: a concise review”, Nanomed. Nanotechol. Biomed., 1: 193-212.
Melgardt, M. D., (2009). “Nanotechnology in drug delivery”., AAPS Press, USA.
Mishra, B., Bhavesh, P., (2010). “Colloidal nanocarriers: A review on formulation technology, types and applications towards targeted drug delivery”, Nanomed. Nanotechol. Biomed., 6: 9-24.
Shelesh, J., Swarnalata, S., (2010). “Type 2 Diabetes Mellitus - Its global prevalence and therapeutic strategies”, Diabetes Metab. Syndrome Clin. Res. Rev., 4: 48-56.
Mihaela, M. M., Helen, L. M., (2011). Glimepiride, a novel sulfonylurea does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide, J. American Heart Association., 103: 3111-3116.
Rhoban, T., (2005). “The efficacy and safety of glimepiride in the management of Type II diabetes in Muslim patients during Ramadan”, Diabetes Care., 28: 421-422.
Vania B. B., (2010). “Preparation of PVP hyrogel nanoparticles using lecithin vesicles”, Quim. Nova., 33:2083-2087.
Tongying, J., Ning, H. (2012). “Enhanced dissolution rate and oral bioavailability of simvastin nanocrystals prepared by sonoprecipitation”, Drug Dev. Ind. Pharm., 38: 1230-1239.
Afe, H., Göpferich, A., (2008). “Polymer coating of quantum dots - a powerful tool towards diagnostics and sensorics”, Eur. J. Pharm. Biopharm., 68: 138-152.
Sohelia, K., Abbas, H. A., (2011) “New surface-modified solid lipid nanoparticles using N-glutaryl phosphatidylethanolamine as the outer shell”, Int. J. Nanomed., 6: 2393-2401.
Baliar, S., Biswal, S., (2009). “Physiochemical properties of glimepiride in solid dispersions with polyethylene glycol 20000”, Int. J. Pharm. Sci. Nano., 2: 537-543.
Blagden, N., Maras, M., (2007). “Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates”, Adv. Drug Deliver. Rev., 59: 617-630.
Fuminori, I., Hiroyuki, F., (2008). “Effect of polyethylene glycol on preparation of rifampicin-loaded PLGA microspheres with membrane emulsification technique”, Colloids Surf. B: Biointerfaces., 66: 65-70.
Min, S. K., Shun, J. J., (2008). “Preparation, characterization and in vivo evaluation of amorphous atrovastatin calcium nanoparticles using supercritical antisolvent (SAS) process”, Eur. J. Pharm. Biopharm., 69: 454-465.
Hui, S. W., Kuhl, T. L., (1999). “Use of polyethyene glycol to control cell aggregation and fusion”. Colloids Surf. B: Biointerfaces., 4, 213-222.
Shubhadeep, C., Subhabrota, M., (2010). “Statistical optimization of fixed dose combination of glimepiride and atrovastatin calcium in immediate release tablet formulation”, Int. J. Pharm. Sci., 2: 194-200.
Korsmeyer, R. W., Gurny, R., (1983). “Mechanism of solute release from porous hydrophilic polymers”, Int. J. Pharm., 15: 25-35.
Kim, H., Fassihi, R., (1997). “Application of binary polymer system in drug release rate modulation and influence of formulation variables and hydrodynamic conditions on release kinetics”, J. Pharm. Sci., 86: 323-328.
Hörter, D., Dressman, J. B., (1997). “Influence of physiochemical properties on dissolution of drugs in the gastrointestinal tract”, Adv. Drug Deliver. Rev., 25: 3-14.
Kaili, H., Shan, C., (2012). “Enhanced oral bioavailability of doxetaxel by lecithin nanoparticles: Preparation, in vitro and in vivo evaluation”. Int. J. Nano. Med.,7: 3537-3545
Zhipeng, C., Lu, X., (2012). “Novel materials which possess the ability to target liver cells”. Drug Delivery., 9: 649-656.
Sajeev, K. B., Saraswathi, R., (2011). “Formulation and evaluation of controlled release glimepiride osmotic systems”,Int. J. Pharm. Res., 3: 79-84.
Kaili, H., Shan, C., (2012). “Enhanced oral bioavailability of doxetaxel by lecithin nanoparticles: Preparation, in vitro and in vivo evaluation”, Int. J. Nano. Med. 7: 3537-3545.
Brown, N. J., Read, N. W., (1990). “Characteristics of lipid substance activating the ideal break in the rat”, Gut., 31: 1126-1129.
Jane, W., Sabine, G., (2008). “Physicochemical stability of phospholipid-dispersed suspensions of crystalline itraconazole”, Eur. J. Pharm. Biopharm., 69: 1104-1113.
Robash, K. S., Keon., W. K. (2009). “Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin”, Eur. J. Pharm. Sci., 37: 508-513.
Müller, R. H., Jacobs, C., Kayser, O., (2001). “Nanosuspensions as particulate drug formulations in therapy, rationale for development and what we can expect for the future”, Adv. Drug Deliver. Rev., 47: 3-19.
Fuminori, I., Hiroyuki, F., (2008). “Effect of polyethylene glycol on preparation of rifampicin-loaded PLGA microspheres with membrane emulsification technique”. Colloids. Surf. B. Biointerfaces., 66: 65-70.
Avnesh, K., Sudesh, K. Y., (2010). “Biodegradable polymeric nanoparticles based drug delivery systems”, Colloids Surf. B. Biointerfaces., 75: 1-18.
Marie, G., Angelica, V., (2008). “Nanoparticles for drug delivery: The need for precision in reporting particle size parameters”. Eur. J. Pharm. Biopharm., 69: 1-9.
Shasha, R., Yunmei, S., (2012). “Particle size reductions to the nanometer range a promising approach to improve buccal absorption of poorly water-soluble drugs”, Int. J. Nano. Med., 6: 1245-1251.
Tamara, M. (2005). “Soluble polymer conjugates for drug delivery”, Drug Discov. Today Tech., 2: 15-20.
Anju, G., Singhvi, I., (2007). “Simultaneous spectrophotometric estimation of Rosiglitazone maleate and glimepiride in tablet dosage forms”, Indian J. Pharm. Sci., 69: 780-783.
Lisha, W., Yanxia, J., Wei, G., (2015). “Preparation, physical characterization and pharmacokinetic study of paclitaxel nanocrystals”, Drug. Dev. Ind. Pharm., 41: 1343-1352.
Yue, P. F., Yuan, H. L., (2010). “Process, optimization, characterization and evaluation in vivo of oxymatrine-phospholipid complex”, Int. J. Pharm., 387: 139-146.
Yongxue, Z., Chunling, W., (2012). “A frustrating problem, accelerated blood clearance of PEGylated solid nanoparticles following subcutaneous injection in rats”, Eur. J. Pharm. Biopharm., 81: 506-513.
Fu, Q., Sun, J., Zhang, D., “Nimodipine nanocrystals for oral bioavailability improvement: preparation, characterization and pharmacokinetic studies”, Colloids Surf. B. Biointerfaces., 109: 161-166.
Tony, R., Elisabeth., (1991). “Determination of glibenclamide and its major metabolites in human serum and urine by column liquid chromatography”, J. Chrom., 564: 223-233.